Details of the Drug

General Information of Drug (ID: DM3JDRP)

Drug Name

Cladribine

Synonyms

Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine

Indication

Disease Entry	ICD 11	Status	REF
Hairy cell leukaemia	2A82.2	Approved	[1], [2]
Multiple sclerosis	8A40	Phase 3	[3]
Relapsing-remitting multiple sclerosis	8A40.0	Phase 3	[4]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

285.69

Topological Polar Surface Area (xlogp)

0.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Bioavailability: The bioavailability of drug is 34-48% [6]
Clearance: The clearance of drug is 978 +/- 422 mL/h/kg [7]
Elimination: 18% of drug is excreted from urine in the unchanged form [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 5.4 hours [8]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.31502 micromolar/kg/day [9]
Unbound Fraction: The unbound fraction of drug in plasma is 0.79% [8]
Vd: The volume of distribution (Vd) of drug is 9 L/kg [7]

Chemical Identifiers

Formula: C10H12ClN5O3
IUPAC Name: (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
Canonical SMILES: C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
InChI: InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
InChIKey: PTOAARAWEBMLNO-KVQBGUIXSA-N

Cross-matching ID

PubChem CID: 20279
ChEBI ID: CHEBI:567361
CAS Number: 4291-63-8
DrugBank ID: DB00242
TTD ID: D05GJW
VARIDT ID: DR00087
INTEDE ID: DR1918
ACDINA ID: D00951

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine deaminase (ADA)	TTLP57V	ADA_HUMAN	Inhibitor	[10], [11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Equilibrative nucleoside transporter 3 (SLC29A3)	DTZAWTH	S29A3_HUMAN	Substrate	[12]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[13]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[13]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Deoxycytidine kinase (DCK)_{Main DME}	DE9FGNK	DCK_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cladribine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pentostatin	DM0HXDS	Major	Additive myelosuppressive effects by the combination of Cladribine and Pentostatin.	Mature B-cell leukaemia [2A82]	[50]
Ofatumumab	DM295PR	Major	Additive myelosuppressive effects by the combination of Cladribine and Ofatumumab.	Mature B-cell leukaemia [2A82]	[50]
Obinutuzumab	DM3BVAE	Major	Additive immunosuppressive effects by the combination of Cladribine and Obinutuzumab.	Mature B-cell leukaemia [2A82]	[50]
Idelalisib	DM602WT	Major	Additive myelosuppressive effects by the combination of Cladribine and Idelalisib.	Mature B-cell leukaemia [2A82]	[50]
GDC-0199	DMH0QKA	Major	Additive immunosuppressive effects by the combination of Cladribine and GDC-0199.	Mature B-cell leukaemia [2A82]	[50]
Chlorambucil	DMRKE63	Major	Additive myelosuppressive effects by the combination of Cladribine and Chlorambucil.	Mature B-cell leukaemia [2A82]	[50]
IPI-145	DMWA24P	Major	Additive myelosuppressive effects by the combination of Cladribine and IPI-145.	Mature B-cell leukaemia [2A82]	[50]
-----------


⏷ Show the Full List of 7 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cladribine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Thioguanine	DM7NKEV	Major	Additive immunosuppressive effects by the combination of Cladribine and Thioguanine.	Acute myeloid leukaemia [2A60]	[50]
Uracil mustard	DMHL7OB	Major	Additive immunosuppressive effects by the combination of Cladribine and Uracil mustard.	Acute myeloid leukaemia [2A60]	[50]
Midostaurin	DMI6E0R	Major	Additive myelosuppressive effects by the combination of Cladribine and Midostaurin.	Acute myeloid leukaemia [2A60]	[50]
Idarubicin	DMM0XGL	Major	Additive myelosuppressive effects by the combination of Cladribine and Idarubicin.	Acute myeloid leukaemia [2A60]	[50]
Daunorubicin	DMQUSBT	Major	Additive myelosuppressive effects by the combination of Cladribine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[50]
Gilteritinib	DMWQ4MZ	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[51]
Siltuximab	DMGEATB	Major	Additive immunosuppressive effects by the combination of Cladribine and Siltuximab.	Anemia [3A00-3A9Z]	[50]
Nifedipine	DMSVOZT	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Nifedipine.	Angina pectoris [BA40]	[51]
Cilostazol	DMZMSCT	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Cilostazol.	Arterial occlusive disease [BD40]	[51]
Budesonide	DMJIBAW	Major	Additive immunosuppressive effects by the combination of Cladribine and Budesonide.	Asthma [CA23]	[50]
Roflumilast	DMPGHY8	Major	Additive immunosuppressive effects by the combination of Cladribine and Roflumilast.	Asthma [CA23]	[50]
Dupilumab	DMOAD2Y	Major	Additive immunosuppressive effects by the combination of Cladribine and Dupilumab.	Atopic eczema [EA80]	[50]
Chloramphenicol	DMFXEWT	Major	Additive immunosuppressive effects by the combination of Cladribine and Chloramphenicol.	Bacterial infection [1A00-1C4Z]	[50]
Linezolid	DMGFPU2	Major	Additive myelosuppressive effects by the combination of Cladribine and Linezolid.	Bacterial infection [1A00-1C4Z]	[50]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[51]
Valrubicin	DMOYJFK	Major	Additive immunosuppressive effects by the combination of Cladribine and Valrubicin.	Bladder cancer [2C94]	[50]
Temozolomide	DMKECZD	Major	Additive myelosuppressive effects by the combination of Cladribine and Temozolomide.	Brain cancer [2A00]	[50]
Lomustine	DMMWSUL	Major	Additive myelosuppressive effects by the combination of Cladribine and Lomustine.	Brain cancer [2A00]	[50]
Eribulin	DM1DX4Q	Major	Additive immunosuppressive effects by the combination of Cladribine and Eribulin.	Breast cancer [2C60-2C6Y]	[50]
Talazoparib	DM1KS78	Major	Additive myelosuppressive effects by the combination of Cladribine and Talazoparib.	Breast cancer [2C60-2C6Y]	[50]
Ixabepilone	DM2OZ3G	Major	Additive immunosuppressive effects by the combination of Cladribine and Ixabepilone.	Breast cancer [2C60-2C6Y]	[50]
LY2835219	DM93VBZ	Major	Additive immunosuppressive effects by the combination of Cladribine and LY2835219.	Breast cancer [2C60-2C6Y]	[50]
Pralatrexate	DMAO80I	Major	Additive myelosuppressive effects by the combination of Cladribine and Pralatrexate.	Breast cancer [2C60-2C6Y]	[50]
Palbociclib	DMD7L94	Major	Additive myelosuppressive effects by the combination of Cladribine and Palbociclib.	Breast cancer [2C60-2C6Y]	[50]
Mitomycin	DMH0ZJE	Major	Additive immunosuppressive effects by the combination of Cladribine and Mitomycin.	Breast cancer [2C60-2C6Y]	[50]
Thiotepa	DMIZKOP	Major	Additive myelosuppressive effects by the combination of Cladribine and Thiotepa.	Breast cancer [2C60-2C6Y]	[50]
Cabazitaxel	DMPAZHC	Major	Additive myelosuppressive effects by the combination of Cladribine and Cabazitaxel.	Breast cancer [2C60-2C6Y]	[50]
Bosutinib	DMTI8YE	Major	Additive myelosuppressive effects by the combination of Cladribine and Bosutinib.	Breast cancer [2C60-2C6Y]	[50]
Corticotropin	DMP9TWZ	Major	Additive immunosuppressive effects by the combination of Cladribine and Corticotropin.	Chronic kidney disease [GB61]	[50]
PF-04449913	DMSB068	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[50]
Phenylbutazone	DMAYL0T	Major	Additive immunosuppressive effects by the combination of Cladribine and Phenylbutazone.	Chronic pain [MG30]	[50]
Irinotecan	DMP6SC2	Major	Additive myelosuppressive effects by the combination of Cladribine and Irinotecan.	Colorectal cancer [2B91]	[50]
Oxaliplatin	DMQNWRD	Major	Additive immunosuppressive effects by the combination of Cladribine and Oxaliplatin.	Colorectal cancer [2B91]	[50]
Aflibercept	DMT3D5I	Major	Additive immunosuppressive effects by the combination of Cladribine and Aflibercept.	Colorectal cancer [2B91]	[50]
Capecitabine	DMTS85L	Major	Additive myelosuppressive effects by the combination of Cladribine and Capecitabine.	Colorectal cancer [2B91]	[50]
Nimodipine	DMQ0RKZ	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Nimodipine.	Coronary vasospastic disease [BA85]	[51]
Mycophenolic acid	DMU65NK	Major	Additive myelosuppressive effects by the combination of Cladribine and Mycophenolic acid.	Crohn disease [DD70]	[50]
Polatuzumab vedotin	DMF6Y0L	Major	Additive immunosuppressive effects by the combination of Cladribine and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[50]
Axicabtagene ciloleucel	DMYHN59	Major	Additive immunosuppressive effects by the combination of Cladribine and Axicabtagene ciloleucel.	Diffuse large B-cell lymphoma [2A81]	[50]
Flucytosine	DM13VTW	Major	Additive myelosuppressive effects by the combination of Cladribine and Flucytosine.	Endocarditis [BB40-BA42]	[50]
Felbamate	DM1V5ZS	Major	Additive immunosuppressive effects by the combination of Cladribine and Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[50]
Mephenytoin	DM5UGDK	Major	Additive immunosuppressive effects by the combination of Cladribine and Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[50]
Paramethadione	DMR5ZUP	Major	Additive immunosuppressive effects by the combination of Cladribine and Paramethadione.	Epilepsy/seizure [8A61-8A6Z]	[50]
Ethotoin	DMXWOCP	Major	Additive immunosuppressive effects by the combination of Cladribine and Ethotoin.	Epilepsy/seizure [8A61-8A6Z]	[50]
Carbamazepine	DMZOLBI	Major	Additive immunosuppressive effects by the combination of Cladribine and Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[50]
Bay 80-6946	DMLOS5R	Major	Additive immunosuppressive effects by the combination of Cladribine and Bay 80-6946.	Follicular lymphoma [2A80]	[50]
Pentamidine	DMHZJCG	Major	Additive immunosuppressive effects by the combination of Cladribine and Pentamidine.	Fungal infection [1F29-1F2F]	[50]
Avapritinib	DMK2GZX	Major	Additive immunosuppressive effects by the combination of Cladribine and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[50]
Colchicine	DM2POTE	Major	Additive myelosuppressive effects by the combination of Cladribine and Colchicine.	Gout [FA25]	[50]
177Lu-DOTATATE	DMT8GVU	Major	Additive immunosuppressive effects by the combination of Cladribine and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[50]
Procarbazine	DMIK367	Major	Additive immunosuppressive effects by the combination of Cladribine and Procarbazine.	Hodgkin lymphoma [2B30]	[50]
Bleomycin	DMNER5S	Major	Additive immunosuppressive effects by the combination of Cladribine and Bleomycin.	Hodgkin lymphoma [2B30]	[50]
Brentuximab vedotin	DMWLC57	Major	Additive myelosuppressive effects by the combination of Cladribine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[50]
Zidovudine	DM4KI7O	Major	Additive immunosuppressive effects by the combination of Cladribine and Zidovudine.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Cladribine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[50]
Dipyridamole	DMXY30O	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Dipyridamole.	Hypertension [BA00-BA04]	[51]
Fludrocortisone	DMUDIR8	Major	Additive immunosuppressive effects by the combination of Cladribine and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[50]
Auranofin	DMWE2N4	Major	Additive myelosuppressive effects by the combination of Cladribine and Auranofin.	Inflammatory arthropathy [FA2Z]	[50]
Olaratumab	DMNYOIX	Major	Additive immunosuppressive effects by the combination of Cladribine and Olaratumab.	Kaposi sarcoma [2B57]	[50]
Methotrexate	DM2TEOL	Major	Additive myelosuppressive effects by the combination of Cladribine and Methotrexate.	Leukaemia [2A60-2B33]	[50]
Nelarabine	DMB6VEG	Major	Additive myelosuppressive effects by the combination of Cladribine and Nelarabine.	Leukaemia [2A60-2B33]	[50]
DTI-015	DMXZRW0	Major	Additive myelosuppressive effects by the combination of Cladribine and DTI-015.	Liver cancer [2C12]	[50]
Denosumab	DMNI0KO	Major	Additive immunosuppressive effects by the combination of Cladribine and Denosumab.	Low bone mass disorder [FB83]	[50]
Brigatinib	DM7W94S	Major	Additive immunosuppressive effects by the combination of Cladribine and Brigatinib.	Lung cancer [2C25]	[50]
Lurbinectedin	DMEFRTZ	Major	Additive immunosuppressive effects by the combination of Cladribine and Lurbinectedin.	Lung cancer [2C25]	[50]
Osimertinib	DMRJLAT	Major	Additive immunosuppressive effects by the combination of Cladribine and Osimertinib.	Lung cancer [2C25]	[50]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[53]
Belimumab	DM3OBQF	Major	Additive immunosuppressive effects by the combination of Cladribine and Belimumab.	Lupus erythematosus [4A40]	[50]
Primaquine	DMWQ16I	Major	Additive myelosuppressive effects by the combination of Cladribine and Primaquine.	Malaria [1F40-1F45]	[50]
Inotuzumab ozogamicin	DMAC130	Major	Additive myelosuppressive effects by the combination of Cladribine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[50]
Fludarabine	DMVRLT7	Major	Additive myelosuppressive effects by the combination of Cladribine and Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[50]
Acalabrutinib	DM7GCVW	Major	Additive myelosuppressive effects by the combination of Cladribine and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[50]
Clofarabine	DMCVJ86	Major	Additive myelosuppressive effects by the combination of Cladribine and Clofarabine.	Mature B-cell lymphoma [2A85]	[50]
Blinatumomab	DMGECIJ	Major	Additive myelosuppressive effects by the combination of Cladribine and Blinatumomab.	Mature B-cell lymphoma [2A85]	[50]
Ibrutinib	DMHZCPO	Major	Additive myelosuppressive effects by the combination of Cladribine and Ibrutinib.	Mature B-cell lymphoma [2A85]	[50]
Vincristine	DMINOX3	Major	Additive myelosuppressive effects by the combination of Cladribine and Vincristine.	Mature B-cell lymphoma [2A85]	[50]
Teniposide	DMLW57T	Major	Additive immunosuppressive effects by the combination of Cladribine and Teniposide.	Mature B-cell lymphoma [2A85]	[50]
Tisagenlecleucel	DMM9BJD	Major	Additive immunosuppressive effects by the combination of Cladribine and Tisagenlecleucel.	Mature B-cell lymphoma [2A85]	[50]
Mercaptopurine	DMTM2IK	Major	Additive myelosuppressive effects by the combination of Cladribine and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[50]
Ponatinib	DMYGJQO	Major	Additive myelosuppressive effects by the combination of Cladribine and Ponatinib.	Mature B-cell lymphoma [2A85]	[50]
Cytarabine	DMZD5QR	Major	Additive myelosuppressive effects by the combination of Cladribine and Cytarabine.	Mature B-cell lymphoma [2A85]	[50]
Mechlorethamine	DM0CVXA	Major	Additive immunosuppressive effects by the combination of Cladribine and Mechlorethamine.	Mature T-cell lymphoma [2A90]	[50]
Dacarbazine	DMNPZL4	Major	Additive myelosuppressive effects by the combination of Cladribine and Dacarbazine.	Melanoma [2C30]	[50]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[54]
Carfilzomib	DM48K0X	Major	Additive immunosuppressive effects by the combination of Cladribine and Carfilzomib.	Multiple myeloma [2A83]	[50]
Panobinostat	DM58WKG	Major	Additive myelosuppressive effects by the combination of Cladribine and Panobinostat.	Multiple myeloma [2A83]	[50]
Lenalidomide	DM6Q7U4	Major	Additive myelosuppressive effects by the combination of Cladribine and Lenalidomide.	Multiple myeloma [2A83]	[50]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Cladribine and Thalidomide.	Multiple myeloma [2A83]	[55]
Selinexor	DMBD4K3	Major	Additive myelosuppressive effects by the combination of Cladribine and Selinexor.	Multiple myeloma [2A83]	[50]
Belantamab mafodotin	DMBT3AI	Major	Additive immunosuppressive effects by the combination of Cladribine and Belantamab mafodotin.	Multiple myeloma [2A83]	[50]
Elotuzumab	DMEYHG9	Major	Additive immunosuppressive effects by the combination of Cladribine and Elotuzumab.	Multiple myeloma [2A83]	[50]
Daratumumab	DMKCIUZ	Major	Additive myelosuppressive effects by the combination of Cladribine and Daratumumab.	Multiple myeloma [2A83]	[50]
Melphalan	DMOLNHF	Major	Additive myelosuppressive effects by the combination of Cladribine and Melphalan.	Multiple myeloma [2A83]	[50]
Tecfidera	DM2OVDT	Major	Additive immunosuppressive effects by the combination of Cladribine and Tecfidera.	Multiple sclerosis [8A40]	[50]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Cladribine and Siponimod.	Multiple sclerosis [8A40]	[51]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Cladribine and Fingolimod.	Multiple sclerosis [8A40]	[56]
Ocrelizumab	DMEZ2KH	Major	Additive immunosuppressive effects by the combination of Cladribine and Ocrelizumab.	Multiple sclerosis [8A40]	[50]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Cladribine and Ozanimod.	Multiple sclerosis [8A40]	[50]
Deflazacort	DMV0RNS	Major	Additive immunosuppressive effects by the combination of Cladribine and Deflazacort.	Muscular dystrophy [8C70]	[50]
Bexarotene	DMOBIKY	Major	Additive immunosuppressive effects by the combination of Cladribine and Bexarotene.	Mycosis fungoides [2B01]	[50]
Romidepsin	DMT5GNL	Major	Additive immunosuppressive effects by the combination of Cladribine and Romidepsin.	Mycosis fungoides [2B01]	[50]
Decitabine	DMQL8XJ	Major	Additive immunosuppressive effects by the combination of Cladribine and Decitabine.	Myelodysplastic syndrome [2A37]	[50]
Azacitidine	DMTA5OE	Major	Additive myelosuppressive effects by the combination of Cladribine and Azacitidine.	Myelodysplastic syndrome [2A37]	[50]
Nilotinib	DM7HXWT	Major	Additive myelosuppressive effects by the combination of Cladribine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[50]
Ruxolitinib	DM7Q98D	Major	Additive myelosuppressive effects by the combination of Cladribine and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[50]
Imatinib	DM7RJXL	Major	Additive immunosuppressive effects by the combination of Cladribine and Imatinib.	Myeloproliferative neoplasm [2A20]	[50]
Dasatinib	DMJV2EK	Major	Additive myelosuppressive effects by the combination of Cladribine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[50]
Hydroxyurea	DMOQVU9	Major	Additive myelosuppressive effects by the combination of Cladribine and Hydroxyurea.	Myeloproliferative neoplasm [2A20]	[50]
Omacetaxine mepesuccinate	DMPU2WX	Major	Additive immunosuppressive effects by the combination of Cladribine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[50]
Busulfan	DMXYJ9C	Major	Additive myelosuppressive effects by the combination of Cladribine and Busulfan.	Myeloproliferative neoplasm [2A20]	[50]
Inebilizumab	DMI0RHA	Major	Additive immunosuppressive effects by the combination of Cladribine and Inebilizumab.	Nervous system paraneoplastic/autoimmune disorder [8E4A]	[50]
Atezolizumab	DMMF8U0	Major	Additive immunosuppressive effects by the combination of Cladribine and Atezolizumab.	Non-small cell lung cancer [2C25]	[50]
Olaparib	DM8QB1D	Major	Additive immunosuppressive effects by the combination of Cladribine and Olaparib.	Ovarian cancer [2C73]	[50]
Rucaparib	DM9PVX8	Major	Additive myelosuppressive effects by the combination of Cladribine and Rucaparib.	Ovarian cancer [2C73]	[50]
Carboplatin	DMG281S	Major	Additive myelosuppressive effects by the combination of Cladribine and Carboplatin.	Ovarian cancer [2C73]	[50]
Altretamine	DMKLAYG	Major	Additive immunosuppressive effects by the combination of Cladribine and Altretamine.	Ovarian cancer [2C73]	[50]
MK-4827	DMLYGH4	Major	Additive myelosuppressive effects by the combination of Cladribine and MK-4827.	Ovarian cancer [2C73]	[50]
Trimethadione	DM0Q8MZ	Major	Additive immunosuppressive effects by the combination of Cladribine and Trimethadione.	Pancreatic cancer [2C10]	[50]
Streptozocin	DMOF7AT	Major	Additive immunosuppressive effects by the combination of Cladribine and Streptozocin.	Pancreatic cancer [2C10]	[50]
Levamisole	DM5EN79	Major	Additive immunosuppressive effects by the combination of Cladribine and Levamisole.	Parasitic infection [1D0Y-1G2Z]	[50]
Albendazole	DMYZ57N	Major	Additive myelosuppressive effects by the combination of Cladribine and Albendazole.	Parasitic worm infestation [1F90]	[50]
Pemetrexed	DMMX2E6	Major	Additive immunosuppressive effects by the combination of Cladribine and Pemetrexed.	Pleural mesothelioma [2C26]	[50]
Dapsone	DM4LT8A	Major	Additive myelosuppressive effects by the combination of Cladribine and Dapsone.	Pneumonia [CA40]	[50]
Prednisone	DM2HG4X	Major	Additive immunosuppressive effects by the combination of Cladribine and Prednisone.	Postoperative inflammation [1A00-CA43]	[50]
Betamethasone	DMAHJEF	Major	Additive immunosuppressive effects by the combination of Cladribine and Betamethasone.	Postoperative inflammation [1A00-CA43]	[50]
Hydrocortisone	DMGEMB7	Major	Additive immunosuppressive effects by the combination of Cladribine and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[50]
Lonafarnib	DMGM2Z6	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Lonafarnib.	Premature ageing appearance [LD2B]	[57]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[58]
Brodalumab	DMASDQ6	Major	Additive immunosuppressive effects by the combination of Cladribine and Brodalumab.	Psoriasis [EA90]	[50]
Ustekinumab	DMHTYK3	Major	Additive immunosuppressive effects by the combination of Cladribine and Ustekinumab.	Psoriasis [EA90]	[50]
Tildrakizumab	DMLW9HG	Major	Additive immunosuppressive effects by the combination of Cladribine and Tildrakizumab.	Psoriasis [EA90]	[50]
Risankizumab	DMM32GT	Major	Additive immunosuppressive effects by the combination of Cladribine and Risankizumab.	Psoriasis [EA90]	[50]
Ixekizumab	DMXW92T	Major	Additive immunosuppressive effects by the combination of Cladribine and Ixekizumab.	Psoriasis [EA90]	[50]
Everolimus	DM8X2EH	Major	Additive immunosuppressive effects by the combination of Cladribine and Everolimus.	Renal cell carcinoma [2C90]	[50]
Temsirolimus	DMS104F	Major	Additive immunosuppressive effects by the combination of Cladribine and Temsirolimus.	Renal cell carcinoma [2C90]	[50]
Ciclesonide	DM2NA4K	Major	Additive immunosuppressive effects by the combination of Cladribine and Ciclesonide.	Respiratory system disease [CB40-CB7Z]	[50]
Sulindac	DM2QHZU	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Sulindac.	Rheumatoid arthritis [FA20]	[51]
Upadacitinib	DM32B5U	Major	Additive immunosuppressive effects by the combination of Cladribine and Upadacitinib.	Rheumatoid arthritis [FA20]	[50]
Penicillamine	DM40EF6	Major	Additive myelosuppressive effects by the combination of Cladribine and Penicillamine.	Rheumatoid arthritis [FA20]	[50]
Baricitinib	DM4ONW5	Major	Additive immunosuppressive effects by the combination of Cladribine and Baricitinib.	Rheumatoid arthritis [FA20]	[50]
Tocilizumab	DM7J6OR	Major	Additive immunosuppressive effects by the combination of Cladribine and Tocilizumab.	Rheumatoid arthritis [FA20]	[50]
Canakinumab	DM8HLO5	Major	Additive immunosuppressive effects by the combination of Cladribine and Canakinumab.	Rheumatoid arthritis [FA20]	[50]
Tofacitinib	DMBS370	Major	Additive immunosuppressive effects by the combination of Cladribine and Tofacitinib.	Rheumatoid arthritis [FA20]	[50]
Rilonacept	DMGLUQS	Major	Additive immunosuppressive effects by the combination of Cladribine and Rilonacept.	Rheumatoid arthritis [FA20]	[50]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Cladribine and Golimumab.	Rheumatoid arthritis [FA20]	[50]
Dexamethasone	DMMWZET	Major	Additive immunosuppressive effects by the combination of Cladribine and Dexamethasone.	Rheumatoid arthritis [FA20]	[50]
Sarilumab	DMOGNXY	Major	Additive immunosuppressive effects by the combination of Cladribine and Sarilumab.	Rheumatoid arthritis [FA20]	[50]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Cladribine and Leflunomide.	Rheumatoid arthritis [FA20]	[50]
Abatacept	DMSA8RU	Major	Additive immunosuppressive effects by the combination of Cladribine and Abatacept.	Rheumatoid arthritis [FA20]	[50]
Clozapine	DMFC71L	Major	Additive myelosuppressive effects by the combination of Cladribine and Clozapine.	Schizophrenia [6A20]	[50]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Cladribine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[59]
Mogamulizumab	DMISH0Z	Major	Additive immunosuppressive effects by the combination of Cladribine and Mogamulizumab.	Sezary syndrome [2B02]	[50]
Tedizolid	DMG2SKR	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Tedizolid.	Skin and skin-structure infection [1F28-1G0Z]	[50]
Floxuridine	DM04LR2	Major	Additive myelosuppressive effects by the combination of Cladribine and Floxuridine.	Solid tumour/cancer [2A00-2F9Z]	[50]
Dactinomycin	DM2YGNW	Major	Additive immunosuppressive effects by the combination of Cladribine and Dactinomycin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Methylprednisolone	DM4BDON	Major	Additive immunosuppressive effects by the combination of Cladribine and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[50]
Cyclophosphamide	DM4O2Z7	Major	Additive immunosuppressive effects by the combination of Cladribine and Cyclophosphamide.	Solid tumour/cancer [2A00-2F9Z]	[50]
Vinblastine	DM5TVS3	Major	Additive immunosuppressive effects by the combination of Cladribine and Vinblastine.	Solid tumour/cancer [2A00-2F9Z]	[50]
PDX-101	DM6OC53	Major	Additive myelosuppressive effects by the combination of Cladribine and PDX-101.	Solid tumour/cancer [2A00-2F9Z]	[50]
Ifosfamide	DMCT3I8	Major	Additive myelosuppressive effects by the combination of Cladribine and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[50]
Docetaxel	DMDI269	Major	Additive immunosuppressive effects by the combination of Cladribine and Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[50]
Trabectedin	DMG3Y89	Major	Additive myelosuppressive effects by the combination of Cladribine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Mitoxantrone	DMM39BF	Major	Additive immunosuppressive effects by the combination of Cladribine and Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[50]
LEE011	DMMX75K	Major	Additive myelosuppressive effects by the combination of Cladribine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[50]
Etoposide	DMNH3PG	Major	Additive myelosuppressive effects by the combination of Cladribine and Etoposide.	Solid tumour/cancer [2A00-2F9Z]	[50]
Epirubicin	DMPDW6T	Major	Additive immunosuppressive effects by the combination of Cladribine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Prednisolone	DMQ8FR2	Major	Additive immunosuppressive effects by the combination of Cladribine and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[50]
Cisplatin	DMRHGI9	Major	Additive immunosuppressive effects by the combination of Cladribine and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Gemcitabine	DMSE3I7	Major	Additive myelosuppressive effects by the combination of Cladribine and Gemcitabine.	Solid tumour/cancer [2A00-2F9Z]	[50]
Fluorouracil	DMUM7HZ	Major	Additive myelosuppressive effects by the combination of Cladribine and Fluorouracil.	Solid tumour/cancer [2A00-2F9Z]	[50]
Taxol	DMUOT9V	Major	Additive myelosuppressive effects by the combination of Cladribine and Taxol.	Solid tumour/cancer [2A00-2F9Z]	[50]
Doxorubicin	DMVP5YE	Major	Additive immunosuppressive effects by the combination of Cladribine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Vinorelbine	DMVXFYE	Major	Additive myelosuppressive effects by the combination of Cladribine and Vinorelbine.	Solid tumour/cancer [2A00-2F9Z]	[50]
Pomalidomide	DMTGBAX	Major	Additive myelosuppressive effects by the combination of Cladribine and Pomalidomide.	Systemic sclerosis [4A42]	[50]
Plicamycin	DM7C8YV	Major	Additive myelosuppressive effects by the combination of Cladribine and Plicamycin.	Testicular cancer [2C80]	[50]
Eltrombopag	DMOGFIX	Moderate	Decreased clearance of Cladribine due to the transporter inhibition by Eltrombopag.	Thrombocytopenia [3B64]	[51]
Trimetrexate	DMDEA85	Major	Additive immunosuppressive effects by the combination of Cladribine and Trimetrexate.	Toxoplasmosis [1F57]	[50]
Sirolimus	DMGW1ID	Major	Additive myelosuppressive effects by the combination of Cladribine and Sirolimus.	Transplant rejection [NE84]	[50]
Azathioprine	DMMZSXQ	Major	Additive immunosuppressive effects by the combination of Cladribine and Azathioprine.	Transplant rejection [NE84]	[50]
Mycophenolate mofetil	DMPQAGE	Major	Additive myelosuppressive effects by the combination of Cladribine and Mycophenolate mofetil.	Transplant rejection [NE84]	[50]
Belatacept	DMXLYQF	Major	Additive immunosuppressive effects by the combination of Cladribine and Belatacept.	Transplant rejection [NE84]	[50]
Tacrolimus	DMZ7XNQ	Major	Additive immunosuppressive effects by the combination of Cladribine and Tacrolimus.	Transplant rejection [NE84]	[50]
Durvalumab	DM4PVDY	Major	Additive immunosuppressive effects by the combination of Cladribine and Durvalumab.	Ureteral cancer [2C92]	[50]
Acetohydroxamic Acid	DMYX7NI	Major	Additive immunosuppressive effects by the combination of Cladribine and Acetohydroxamic Acid.	Urinary tract infection [GC08]	[50]
Triamcinolone	DM98IXF	Major	Additive immunosuppressive effects by the combination of Cladribine and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[50]
Fluticasone	DMGCSVF	Major	Additive immunosuppressive effects by the combination of Cladribine and Fluticasone.	Vasomotor/allergic rhinitis [CA08]	[50]
Procainamide	DMNMXR8	Major	Additive immunosuppressive effects by the combination of Cladribine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[50]
Tocainide	DMYNMDP	Major	Additive immunosuppressive effects by the combination of Cladribine and Tocainide.	Ventricular tachyarrhythmia [BC71]	[50]
Ganciclovir	DM1MBYQ	Major	Additive immunosuppressive effects by the combination of Cladribine and Ganciclovir.	Virus infection [1A24-1D9Z]	[50]
Trifluridine	DMG2YBD	Major	Additive immunosuppressive effects by the combination of Cladribine and Trifluridine.	Virus infection [1A24-1D9Z]	[50]
Valganciclovir	DMS2IUH	Major	Additive immunosuppressive effects by the combination of Cladribine and Valganciclovir.	Virus infection [1A24-1D9Z]	[50]
-----------


⏷ Show the Full List of 192 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Magnesium stearate	E00208	11177	lubricant
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sorbitan tristearate	E00516	17800859	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Hydroxypropyl betadex	E00697	Not Available	Complexing agent; Modified-release agent; penetration agent; Solubilizing agent; Tonicity agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cladribine 10mg tablet	10mg	Tablet	Oral
Cladribine 1mg/ml injectable	1mg/ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4799).
2	Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	BDDCS applied to over 900 drugs
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10	Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
11	Cladribine. Ortho Biotech Inc. Curr Opin Investig Drugs. 2001 Dec;2(12):1751-6.
12	Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7.
13	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
14	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
15	Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019 May;30:176-186.
16	FDA label of Belinostat. The 2020 official website of the U.S. Food and Drug Administration.
17	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
18	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
19	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
20	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
21	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
22	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
23	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
24	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
25	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
26	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
27	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
28	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
29	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
30	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
31	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
32	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
33	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
34	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
35	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
36	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
37	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
38	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
39	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
40	P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
41	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
42	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
43	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
44	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
45	Clinical pipeline report, company report or official report of GlaxoSmithKline.
46	Clinical pipeline report, company report or official report of Orchard Therapeutics.
47	Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359-67.
48	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
49	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
50	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51	Cerner Multum, Inc. "Australian Product Information.".
52	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
53	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
54	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
55	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
56	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
57	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
58	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
59	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]